title: Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer.
abstract: Nanocarriers have emerged as a powerful alternative for cancer therapy. Indeed, they are promising candidates to tackle the acquired resistance of surviving cells against antiproliferative drugs - the so-called multidrug resistance (MDR) phenomenon - which has arisen as one of the major clinical issues of chemotherapy. Among nanocarriers, this review focuses on the recent approaches based on tailored mesoporous silica nanoparticles (MSNs) that could overcome this problem. Areas covered: Herein we summarize the current efforts developed to provide MSN-based nanosystems of enhanced dual therapeutic action against diseased cells. This can be accomplished by three main approaches: i) increasing nanosystems' killing capability towards particular cells by enhancing both recognition and specificity; ii) increasing the apoptotic effect throughout co-delivery of several drugs; or iii) combining drug delivery with apoptosis induced by physical methods. Expert opinion: The development of multifunctional nanosystems able to exert the optimal therapeutic action through the minimal administration constitutes a major challenge in nanomedicine. Recent developments in advanced MSN-based platforms for drug delivery represent promising avenues in the management of MDR associated with cancer therapy. All strategies discussed in this manuscript demonstrate improvements against difficult-to-treat tumors.
authors.affiliation: a Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia , Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12 , Madrid , Spain.|b Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Madrid , Spain.
authors.forename: Rafael R
authors.initials: RR
authors.lastname: Castillo
authors.affiliation: a Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia , Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12 , Madrid , Spain.|b Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Madrid , Spain.
authors.forename: Montserrat
authors.initials: M
authors.lastname: Colilla
authors.affiliation: a Departamento de Química Inorgánica y Bioinorgánica. Facultad de Farmacia , Universidad Complutense de Madrid, Instituto de Investigación Sanitaria Hospital 12 de Octubre i+12 , Madrid , Spain.|b Center on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) , Madrid , Spain.
authors.forename: María
authors.initials: M
authors.lastname: Vallet-Regí
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D016503:Drug Delivery Systems; D018432:Drug Resistance, Multiple; D006801:Humans; D050997:Nanomedicine; D053758:Nanoparticles; D009369:Neoplasms / Q000188:drug therapy*; D016062:Porosity; D012822:Silicon Dioxide / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D012822:Silicon Dioxide
keywords: Cancer treatment; co-delivery; combination therapy; dual targeting; mesoporous silica nanoparticles; multidrug resistance